The international society of doctors and scientists who study histiocytic disorders; its LCH trials, run since the 1990s, set the worldwide standard for treating Langerhans cell histiocytosis in children.
Founded in 1985, the Histiocyte Society brings together clinicians and researchers working on Langerhans cell histiocytosis, haemophagocytic lymphohistiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease and juvenile xanthogranuloma. It has run the sequential international LCH-I (1991), LCH-II, LCH-III (2001-2008) and LCH-IV trials, which established vinblastine-prednisone as standard therapy and defined its duration, and the HLH-94 and HLH-2004 protocols. It publishes classification and consensus guidelines, holds an annual scientific meeting, and maintains registries that supported the recognition of histiocytoses as MAPK-driven clonal neoplasms.
Shares Rare and paediatric cancers without markets and the tag paediatric.
Shares Rare and paediatric cancers without markets and the tag paediatric.
Shares LCH-III, Langerhans cell histiocytosis (LCH), Vinblastine and the tag paediatric.
Shares LCH-III, Langerhans cell histiocytosis (LCH), Vinblastine and the tag paediatric.
Shares Rare and paediatric cancers without markets and the tag paediatric.
Shares Rare and paediatric cancers without markets and the tag paediatric.
Shares Rare and paediatric cancers without markets and the tag paediatric.
Shares Vinblastine, Rare and paediatric cancers without markets and the tag paediatric.